No Data
No Data
Xiangxue Pharmaceutical Co.,Ltd.'s (SZSE:300147) Price Is Right But Growth Is Lacking After Shares Rocket 25%
The function of xiangxue pharmaceutical (300147.SZ) product Huoxiang Zhengqi mixture is to release exterior and transform dampness, regulate qi and harmonize the middle burner.
Xiangxue Pharmaceutical (300147.SZ) stated on its investor interaction platform on July 31st that the company's product, Huoxiang Zhengqi Oral Liquid, functions to disperse exterior pathogenic factors and resolve dampness, regulate qi and harmonize the middle. It is used for summer dampness cold, headache, body heaviness and chest tightness, or cold and fever with abdominal distension, vomiting, and diarrhea.
A-share noon report: Shanghai Composite Index rose 1.79%, Chinext Price Index rose 3.33%, nearly 5000 stocks rose! Brokerage stocks surged across the board.
As of noon closing, the Shanghai Composite Index rose 1.79% to 2930.8 points, the Shenzhen Component Index rose 2.96%, and the chinext price index rose 3.33%. Nearly 5000 stocks have risen.
Xiangxue Pharmaceutical (300147.SZ) intends to transfer 51% of the equity of its subsidiary Peking Xiangxue.
Xiangxue Pharmaceutical (300147.SZ) announced on July 19 that in order to further integrate resources, improve overall operation level, and orderly resolve corporate debt risks based on strategic planning and business development, Guangzhou Xiangxue Pharmaceutical Co., Ltd. has signed an equity transfer agreement with Beijing Liuguitang Enterprise Management Technology Co., Ltd. (referred to as "Beijing Liuguitang"), transferring 51% equity of its holding subsidiary Beijing Xiangxue Pharmaceutical Biotechnology Co., Ltd. (referred to as "Beijing Xiangxue") at a price of 23.868 million yuan.
Xiangxue Pharmaceutical (300147.SZ) achieved stable growth of revenue in 2023, with revenue growth of over 100% in the core business of Chinese patent medicine.
On July 16th, Gelonghui reported that Xiangxue Pharmaceutical (300147.SZ) stated on the investor interaction platform that with the continuous deepening of medical reform and the continuous promotion of relevant policies by the country, the pharmaceutical industry is undergoing systematic governance across the entire field, chain, and coverage. Facing various unexpected challenges such as the complex external environment, heavy internal debt burden, and large operational pressure, the company always puts product quality at the forefront of corporate development, actively responds to challenges, vigorously explores new markets, promotes the development of core business, and achieves stable revenue growth in 2023, with revenue growth in the core business of Chinese patent medicine sector.
Xiangxue Pharmaceutical (300147.SZ): The main research direction in the forefront of biotechnology and pharmaceutical R&D is T cell immunotherapy technology. The main products include TAEST16001, TAEST1901, etc.
On July 15th, GeLongHui reported that Xiangxue Pharmaceutical (300147.SZ) stated on an investor interaction platform that the company's main research direction in the forefront of biotechnology and pharmaceutical research and development is T-cell immunotherapy technology. The main products include TAEST16001, TAEST1901, etc. The TAEST16001 injection development project is mainly used to treat synovial sarcoma and is currently in the phase II clinical research stage of new drug registration clinical trials, which is being systematically promoted. The TAEST1901 injection development project is mainly used to treat primary liver cancer and is currently in the stage of initiating phase I clinical research.
No Data